Alnylam Pharmaceuticals (ALNY) Return on Equity (2010 - 2026)

Alnylam Pharmaceuticals has reported Return on Equity for 17 years, with the latest figure at 0.01% in Q1 2026.

• For the quarter ending Q1 2026, Return on Equity rose 2.0% year-over-year to 0.01%; the trailing twelve-month figure through Mar 2026 stood at 0.01% (up 2.0% YoY), and the FY2025 full-year result was 0.01%, down 3.0% from the prior year.
• Return on Equity for Q1 2026 stood at 0.01%, down from 0.01% in the prior quarter.
• The five-year high for Return on Equity was 0.1% in Q4 2022, with the low at 0.23% in Q3 2024.
• Historically, Return on Equity has averaged 0.02% across 5 years, with a median of 0.01% in 2026.
• Annual changes were most pronounced in 2023 — Return on Equity gained 24 bps — and 2024, when it retreated 24 bps.
• Alnylam Pharmaceuticals' Return on Equity stood at 0.1% in 2022, then sank by 77 bps to 0.02% in 2023, then tumbled by 346 bps to 0.06% in 2024, then jumped by 111 bps to 0.01% in 2025, then decreased by 7 bps to 0.01% in 2026.
• The last three Return on Equity figures came in at 0.01% (Q1 2026), 0.01% (Q4 2025), and 0.01% (Q3 2025), per Business Quant data.